Boston Scientific Makes A Move In Mitral Valve, Sealing $325M Deal With Millipede
Executive Summary
Boston Scientific has acquired the remaining shares of privately held mitral-valve repair device company Millipede for $325m.
You may also be interested in...
Device/Diagnostics Quarterly Dealmaking Statistics, Q4 2018
Device fundraising in the fourth quarter totaled $1.5bn, a 42% decrease from Q3's $2.6bn. Q4 M&A activity reached $8.6bn. Q4 diagnostics financings brought in $1.2bn (a 32% increase over Q3) and M&As totaled $1.3bn (the second-highest quarter of the year).
Boston Scientific Hooks In Millipede, But Still Trailing Behind In Mitral Valve Race
Boston Scientific is pumping money into the high-potential mitral valve repair space by making a strategic investment in Millipede, as well as signing an acquisition option agreement that could be worth nearly half a billion dollars. However, its cardiovascular rivals are already some distance ahead in this space.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.